Jinling Pharmaceutical Co., Ltd. (000919)

Jinling Pharmaceutical Co., Ltd. (000919)

Jinling Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinling pharmaceutical") was formally established on September 8, 1998. On August 27, 1999, the company issued 80 million A-share shares in Shenzhen Stock Exchange and listed on November 18, 1999 (Stock Code: 000919).

In November 1998, Jinling pharmaceutical was transferred from Nanjing Military Region to Nanjing City, which is subordinate to Nanjing SASAC. Its controlling shareholder is Nanjing Xingong Investment Group Co., Ltd., which holds 45.23% of the company's shares.

The company has two industrial platforms of medicine and health care. The pharmaceutical section has a production capacity of nearly 100 specifications of Chinese and Western medicines, including Mailuoning injection, sulifei and other well-known products. At present, the medical, health and nursing section holds three general hospitals and one integrated project company of medical, health and nursing. Among them, Suqian people's Hospital of Nanjing Gulou Hospital Group is a class III first-class hospital, Yizheng Hospital of Nanjing Gulou Hospital Group and Anqing Petrochemical Hospital of Nanjing Gulou Hospital Group are class II first-class hospitals; Huzhou Social Welfare Center Development Co., Ltd. (Huzhou social welfare center, Huzhou veteran cadre rehabilitation center, Huzhou rehabilitation hospital) is a four-star pension institution, which has basically formed a complete big health service format Integrating Medicine, health and nursing.

The company always adheres to the business philosophy of "seeking steadiness in development and development in steadiness", thinking of danger in times of peace and striving constantly. Now, we are striving to become a listed company with remarkable economic and social benefits, outstanding competitive advantages, high-quality development and industry influence.

>>server parts deals for server parts picker Tungsten Rings for Men and Women boxingcsk